Richard F. Kefford
#137,071
Most Influential Person Now
Researcher
Richard F. Kefford's AcademicInfluence.com Rankings
Richard F. Keffordcomputer-science Degrees
Computer Science
#6339
World Rank
#6686
Historical Rank
Artificial Intelligence
#2276
World Rank
#2315
Historical Rank
Database
#3437
World Rank
#3581
Historical Rank
Download Badge
Computer Science
Richard F. Kefford's Degrees
- PhD Computer Science Stanford University
- Masters Artificial Intelligence University of California, Berkeley
Similar Degrees You Can Earn
Why Is Richard F. Kefford Influential?
(Suggest an Edit or Addition)Richard F. Kefford's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. (2013) (3189)
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. (2012) (2458)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. (2012) (2035)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial (2014) (1524)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma (2017) (964)
- Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. (2011) (957)
- Whole-genome landscapes of major melanoma subtypes (2017) (875)
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial (2012) (835)
- Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. (2014) (835)
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. (2016) (831)
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. (2012) (819)
- Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. (2013) (681)
- Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance (2012) (614)
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma (2011) (578)
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. (2016) (572)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. (2016) (468)
- Genome-wide association study identifies three loci associated with melanoma risk (2009) (444)
- Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. (2013) (432)
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact (2014) (430)
- A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma (2011) (414)
- High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. (2006) (401)
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma (2012) (392)
- Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents (2006) (384)
- Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. (2013) (381)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials (2015) (342)
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. (2017) (310)
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019) (307)
- Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. (2010) (291)
- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma (2013) (286)
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma (2014) (280)
- Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. (2016) (256)
- Genome-wide association study identifies three new melanoma susceptibility loci (2011) (252)
- Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. (2016) (248)
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
- Common sequence variants on 20q11.22 confer melanoma susceptibility (2008) (238)
- Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial (1994) (234)
- Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma (2017) (234)
- Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. (1989) (233)
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (2019) (228)
- Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. (1999) (222)
- Sunbed use during adolescence and early adulthood is associated with increased risk of early‐onset melanoma (2011) (215)
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors (2014) (209)
- Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. (2015) (206)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab (2018) (195)
- Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies (2018) (192)
- A melanoma-associated germline mutation in exon 1β inactivates p14ARF (2001) (192)
- Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. (2017) (190)
- Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study (2016) (188)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. (2013) (185)
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy (2018) (184)
- Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. (1982) (183)
- BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. (2013) (181)
- Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. (2014) (179)
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma (2018) (176)
- Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma (2008) (174)
- Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. (2017) (172)
- Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma (2017) (171)
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials (2015) (169)
- Selection criteria for genetic assessment of patients with familial melanoma. (2009) (168)
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) (2013) (157)
- A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. (2014) (157)
- Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. (1993) (148)
- Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3 (2011) (146)
- Targeting BRAF for patients with melanoma (2010) (144)
- BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. (2011) (142)
- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). (2014) (140)
- Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial (2009) (135)
- Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. (2011) (133)
- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). (2011) (132)
- Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. (1993) (127)
- Cutaneous melanoma (2005) (127)
- Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma (2016) (126)
- Localization of a novel melanoma susceptibility locus to 1p22. (2003) (124)
- CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas (1999) (124)
- Cutaneous melanoma in the era of molecular profiling (2009) (123)
- Mutations in the INK4a/ARF Melanoma Susceptibility Locus Functionally Impair p14ARF * (2001) (121)
- PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients (2015) (121)
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition (2020) (119)
- Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. (2015) (117)
- Locally advanced and inflammatory breast cancer. (2005) (112)
- Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. (1995) (111)
- Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. (2013) (111)
- Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma (2017) (110)
- BRAF inhibitor activity in V600R metastatic melanoma. (2013) (110)
- Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma (2014) (105)
- Differential expression of a novel gene, WDNM1, in nonmetastatic rat mammary adenocarcinoma cells. (1988) (105)
- Genetic testing for melanoma. (2002) (104)
- Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (2016) (104)
- Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. (2014) (103)
- Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. (1987) (102)
- Prediction of life-expectancy in hospice patients: identification of novel prognostic factors (1993) (102)
- Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. (2007) (101)
- Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization (2000) (100)
- Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. (2012) (98)
- Association between circulating white blood cell count and cancer mortality: a population-based cohort study. (2006) (97)
- The ARF tumour suppressor. (2006) (96)
- Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma (2014) (95)
- Immune checkpoint inhibitors in melanoma. (2015) (95)
- Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. (2019) (94)
- Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus. (1992) (87)
- Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. (2015) (87)
- A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma (2009) (86)
- Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. (2012) (86)
- A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. (1989) (85)
- Sequence and evolution of the human T-cell antigen receptor beta-chain genes. (1985) (82)
- Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases (2016) (81)
- Residual FDG‐PET metabolic activity in metastatic melanoma patients with prolonged response to anti‐PD‐1 therapy (2016) (81)
- Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. (2016) (81)
- Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. (2015) (79)
- Evaluation of commercial kits for purification of circulating free DNA. (2018) (78)
- Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine (2012) (78)
- Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma (2014) (78)
- The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence (2009) (76)
- The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition (2014) (75)
- Intrapatient Homogeneity of BRAFV600E Expression in Melanoma (2014) (72)
- IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence (2010) (71)
- Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. (1994) (70)
- Hereditary melanoma in Australia. Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. (1991) (70)
- Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma (2013) (69)
- Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors. (2009) (68)
- PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors (2017) (64)
- Purine deoxynucleoside toxicity in nondividing human lymphoid cells. (1982) (64)
- p14ARF Interacts with the SUMO-Conjugating Enzyme Ubc9 and Promotes the Sumoylation of Its Binding Partners (2005) (64)
- Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment (2014) (64)
- Liquid biomarkers in melanoma: detection and discovery (2018) (63)
- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. (2020) (63)
- Loss of heterozygosity in malignant melanoma at loci on chromosomes 11 and 17 implicated in the pathogenesis of other cancers (1993) (62)
- The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a (2009) (62)
- A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. (2015) (61)
- Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. (1992) (61)
- Association of p14ARF with the p120E4FTranscriptional Repressor Enhances Cell Cycle Inhibition* (2003) (61)
- Is there a role for genetic testing in patients with melanoma? (2003) (60)
- Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor (2014) (59)
- Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma (2018) (59)
- Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study (2016) (59)
- Serum β2-microglobulin binds to a T-cell differentiation antigen and increases its expression (1984) (58)
- Population-based, case-control-family design to investigate genetic and environmental influences on melanoma risk: Australian Melanoma Family Study. (2009) (58)
- INTRACAVITARY ADRIAMYCIN NITROGEN MUSTARD AND TETRACYCLINE IN THE CONTROL OF MALIGNANT EFFUSIONS: A RANDOMIZED STUDY (1980) (57)
- Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. (2014) (57)
- Deoxycoformycin‐induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non‐replicating lymphocytes (1982) (57)
- Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. (2012) (57)
- G1-phase arrest of cultured human leukemic T-cells induced by deoxyadenosine. (1981) (57)
- A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma (2005) (57)
- Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding. (2001) (57)
- Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib (2014) (56)
- p16INK4a-induced senescence is disabled by melanoma-associated mutations (2008) (56)
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. (2019) (56)
- Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). (2014) (55)
- Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma. A marker of neural crest origins? (1991) (54)
- Transcriptional down-regulation of a rat gene, WDNM2, in metastatic DMBA-8 cells. (1989) (52)
- Absence of distinguishing senescence traits in human melanocytic nevi. (2012) (52)
- p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. (2008) (51)
- The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma (2014) (51)
- Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. (2015) (51)
- Oncogenic signaling in uveal melanoma (2018) (50)
- Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients (2014) (50)
- A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy (2010) (50)
- Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom (2014) (50)
- Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697) . (2011) (50)
- Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma (2019) (49)
- Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. (2016) (49)
- Stimulation of HLA‐A,B,C by IFN‐alpha. The derivation of Molt 4 variants and the differential expression of HLA‐A,B,C subsets. (1985) (49)
- Human Cancer Biology Distinguishing Clinicopathologic Features of Patients with V 600 E and V 600 K BRAF-Mutant Metastatic Melanoma (2012) (47)
- Adjuvant therapy of cutaneous melanoma: the interferon debate. (2003) (46)
- Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. (2017) (46)
- Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. (2013) (46)
- Early-life sun exposure and risk of melanoma before age 40 years (2011) (46)
- Assessing the Incremental Contribution of Common Genomic Variants to Melanoma Risk Prediction in Two Population-Based Studies (2018) (46)
- Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling (2014) (45)
- Paradoxical oncogenesis: are all BRAF inhibitors equal? (2013) (44)
- Oncogenic B-RAFV600E signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion (2012) (44)
- Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma (2014) (44)
- Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. (2014) (44)
- The spectrum of in vitro radiosensitivity in four human melanoma cell lines is not accounted for by differential induction or rejoining of DNA double strand breaks. (1995) (44)
- (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. (2013) (43)
- Amplification of c‐ras‐ki oncogene in human ovarian tumours (1989) (43)
- Patterns of response and progression in patients with BRAF‐mutant melanoma metastatic to the brain who were treated with dabrafenib (2014) (43)
- Identification of a melanoma susceptibility locus and somatic mutation in TET2. (2014) (43)
- Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. (2014) (42)
- Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9‐mb interval (2004) (42)
- Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors (2015) (42)
- Cutaneous adverse events in patients treated with BRAF inhibitor‐based therapies for metastatic melanoma for longer than 52 weeks (2015) (42)
- Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK (2011) (41)
- Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors (2013) (41)
- Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). (2011) (41)
- Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome (2014) (41)
- The WDNM1 gene product is a novel member of the 'four-disulphide core' family of proteins. (1991) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression (2013) (40)
- Predicting functional significance of cancer‐associated p16INK4a mutations in CDKN2A (2010) (40)
- Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. (2015) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients (2014) (38)
- O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib (2009) (38)
- Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy (2008) (37)
- BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma (2013) (37)
- Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). (2017) (37)
- MC1R genotypes and risk of melanoma before age 40 years: A population‐based case‐control‐family study (2012) (36)
- 1220PDPhase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma (2017) (36)
- Metastasis‐specific patterns of response and progression with anti‐PD‐1 treatment in metastatic melanoma (2018) (35)
- Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors (2020) (35)
- 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. (2018) (35)
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. (2019) (35)
- P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma (2015) (35)
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. (2019) (34)
- Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series (2016) (33)
- RENAL PHOSPHATE THRESHOLD AND RESPONSE TO PAMIDRONATE IN HUMORAL HYPERCALCAEMIA OF MALIGNANCY (1989) (33)
- Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386) (2018) (33)
- Secondary c‐Kit mutations confer acquired resistance to RTK inhibitors in c‐Kit mutant melanoma cells (2013) (33)
- Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). (2014) (33)
- Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma (2012) (33)
- PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. (2016) (32)
- Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. (1999) (32)
- Responses to ultraviolet-B in cell lines from hereditary melanoma kindreds (2001) (32)
- Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility (2018) (32)
- Enforced Expression of p14ARF Induces p53-Dependent Cell Cycle Arrest but Not Apoptosis (2005) (32)
- Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. (2013) (31)
- Ipilimumab‐induced hypophysitis in melanoma patients: an Australian case series (2015) (31)
- p14ARF Regulates E2F-1 Ubiquitination and Degradation via a p53-Dependent Mechanism (2007) (31)
- LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES (2014) (30)
- MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study (2013) (30)
- Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) (2012) (29)
- BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). (2013) (29)
- Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations (2018) (29)
- New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. (2015) (29)
- Demonstration of somatic rearrangements and genomic heterogeneity in human ovarian cancer by DNA fingerprinting. (1990) (28)
- The molecular profile of metastatic melanoma in Australia. (2016) (27)
- Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). (2014) (27)
- Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia (2013) (27)
- X inactivation, DNA deletion, and microsatellite instability in common acquired melanocytic nevi. (2001) (26)
- Clinicians’ attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literature (2020) (26)
- A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma (2009) (26)
- Differential expression of p16INK4a and p16β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations (1997) (26)
- Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients (2017) (26)
- Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. (2016) (25)
- Molecular oncogenetics of metastasis. (1990) (25)
- Physical and Functional Interaction of the p14ARF Tumor Suppressor with Ribosomes* (2006) (25)
- Interferon Signaling Is Frequently Downregulated in Melanoma (2018) (24)
- Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. (2019) (24)
- Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. (2014) (24)
- p16INK4a deficiency promotes DNA hyper‐replication and genetic instability in melanocytes (2013) (23)
- Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma (2005) (23)
- Loss of keratin expression in anaplastic carcinoma cells due to posttranscriptional down-regulation acting in trans. (1992) (23)
- Optimizing combination dabrafenib and trametinib therapy in BRAF mutation‐positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists (2016) (23)
- Amplification of HER-2/neu oncogene in human ovarian cancer (1992) (23)
- BRAF mutation by age-decade and body mass index in metastatic melanoma. (2011) (22)
- Harvey-ras oncogene restriction fragment alleles in familial melanoma kindreds. (1986) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma (2012) (21)
- 10q deletions in metastatic cutaneous melanoma. (1998) (21)
- Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells. (1993) (20)
- The use of L-dopa and carbidopa in metastatic malignant melanoma. (1991) (20)
- Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). (2015) (20)
- Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma (2020) (20)
- Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas (2014) (20)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (20)
- Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. (2015) (19)
- Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. (2005) (19)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013 (2014) (19)
- whole-exome sequencing identifies (2016) (19)
- Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors (2013) (18)
- Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: nondurable chemotherapy responses without clinically meaningful graft-vs-tumor (GVT) effects. (2002) (18)
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (18)
- BRAF inhibitor activity in V600R metastatic melanoma--response. (2013) (17)
- Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B (2020) (17)
- Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohort (2016) (16)
- S-adenosylhomocysteine hydrolase inhibition in deoxyadenosine-treated human T-lymphoblasts and resting peripheral blood lymphocytes. (1982) (16)
- Amino terminal hydrophobic import signals target the p14ARF tumor suppressor to the mitochondria (2010) (16)
- Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer (1992) (16)
- Carboplatin-containing regimens for small cell lung cancer: implications for management in the elderly. (1992) (16)
- Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. (2013) (16)
- Medical heat for climate change (2006) (16)
- Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma (2007) (16)
- Patterns of metastases in familial and non-familial melanoma (2003) (16)
- Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA (2020) (15)
- Terminal incorporation of 2'-deoxyadenosine into polyadenylate segments of polyadenylated RNA in G1-phase-arrested human T-lymphoblasts. (1983) (15)
- Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC) (2014) (15)
- Somatic variants of the level of expression of a cell surface antigen. (1983) (15)
- Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM). (2014) (14)
- Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. (2018) (14)
- Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. (2020) (13)
- Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma (2019) (13)
- Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing (2017) (13)
- Causes of deaths in an oncology unit. (1981) (13)
- Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD). (2013) (12)
- Treatment Algorithms in Stage IV Melanoma (2015) (12)
- 604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial (2012) (12)
- Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma. (2016) (12)
- Post‐transcriptional regulation of urokinase plasminogen activator gene expression occurs in the nucleus of BC1 rat mammary tumor cells (1992) (12)
- Frequent loss of heterozygosity targeting the inactive X chromosome in melanoma. (2003) (12)
- Drug treatment for melanoma: progress, but who pays? (2012) (12)
- Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure (2019) (11)
- Lack of correlation between immunoglobulin and T cell receptor gene rearrangements and TdT expression in acute myeloid leukaemia. (1990) (11)
- Phorbol esters potentiate the induction of class I HLA expression by interferon alpha. (1989) (11)
- Selective loss of wild-type p16(INK4a) expression in human nevi. (2011) (11)
- Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. (2015) (11)
- Oncogenic B-RAF(V600E) promotes anchorage-independent survival of human melanocytes. (2010) (11)
- Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: an overview. (1989) (11)
- 3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate (2015) (10)
- Conservation and potential role of RNA-instability motifs in urokinase gene 3'-untranslated sequences. (1991) (10)
- Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma. (2018) (10)
- Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab (2018) (10)
- KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma. (2017) (10)
- 616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma (2012) (9)
- Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification. (2018) (9)
- Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
- Clinical aspects of hereditary melanoma in Australia. (1992) (9)
- Activity of recombinant human interleukin-21 (rIL-21) in patients (pts) with stage IV malignant melanoma (MM) without prior treatment: Clinical data from a phase IIa study (2008) (9)
- Flow cytometric analysis of adenosine analogue lymphocytotoxicity. (1983) (9)
- Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763). (2014) (9)
- Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia (2017) (9)
- A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. (2013) (9)
- First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies (2021) (9)
- Hypertrophic osteoarthropathy from pulmonary metastatic phyllodes tumour of the breast (2004) (8)
- A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status (2013) (8)
- Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436). (2012) (8)
- Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy. (2014) (8)
- Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma. (1991) (8)
- RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers (2014) (8)
- Melanoma - a management guide for GPs. (2012) (8)
- Reply to K.S. Wilson et al. (2013) (8)
- Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM). (2017) (8)
- Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin. (1998) (8)
- Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). (2013) (8)
- Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis (2017) (7)
- Long-Term Outcomes in Patients With BRAF V 600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy : Analysis From Phase 2 and 3 Clinical Trials (2021) (7)
- Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma. (2010) (7)
- Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial (2020) (7)
- Systemic treatments for metastatic cutaneous melanoma: (Protocol) (2014) (7)
- Intravascular metastatic melanoma: A difficult diagnosis (2013) (7)
- The melanoma‐associated 24 base pair duplication in p16INK4a is functionally impaired (2005) (7)
- Multiple levels of post‐transcriptional regulation of collagenase (matrix metalloproteinase 1) in an epithelial cell line (1993) (7)
- Intranuclear post-transcriptional down-regulation responsible for loss of a keratin differentiation marker in tumour progression. (1995) (7)
- Melanoma management in 2007. (2007) (6)
- BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
- Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma (2015) (6)
- Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation (2013) (6)
- 600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors (2012) (6)
- Molecular models of tumorigenesis: application to familial and sporadic melanoma. (1988) (6)
- Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma. (2015) (6)
- Hypermethylation of Circulating Free DNA in Cutaneous Melanoma (2019) (6)
- Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom (2014) (6)
- Normal repair of ultraviolet radiation-induced DNA damage in familial melanoma without CDKN2A or CDK4 gene mutation. (1999) (6)
- Pneumocystis jirovecii in a patient on dose‐dense chemotherapy for early breast cancer (2019) (6)
- Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi). (2011) (6)
- Single institutional experience with non-seminomatous germ cell tumours of the testis: local perspectives on a curable cancer. (1991) (6)
- Diffuse melanosis cutis in the setting of BRAFV600E mutant melanoma and treatment with targeted therapies (2015) (5)
- 140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475) (2014) (5)
- Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study. (2010) (5)
- Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma. (2017) (5)
- 3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma (2015) (5)
- Isolation and preliminary characterisation of an X-ray-sensitive mammalian mutant cell line (WMXRS-1). (1994) (5)
- Association Between Circulating White Blood Cell Count and Cancer Mortality (2016) (5)
- Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF-kinase in BRAF-mutant metastatic melanoma. (2011) (5)
- Management of the patient with advanced melanoma (2003) (5)
- Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer (2004) (5)
- Phase II trial of iboctadekin (rhIL-18) on a daily X 5 schedule in metastatic melanoma (MM). (2006) (5)
- Characteristics of pyrexia in BRAF V 600 E / K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I / II clinical trial (2015) (4)
- Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma. (2014) (4)
- Mutation analysis of CDKN2A and CDK4 in familial melanoma: 463 (1997) (4)
- Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors (2020) (4)
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition (2020) (4)
- Linkage analysis of familial melanoma and chromosome 6 in 14 Australian kindreds (1997) (4)
- Purinogenic lymphocytotoxicity: Clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors (2004) (4)
- Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436). (2012) (4)
- SCL gene in human tumors. (1992) (4)
- LBA6_PRCOMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanoma (2017) (4)
- Unregulated and independent expression of collagenase and transin related to tumor progression. (1993) (4)
- Clinicians’ attitudes to oncology clinical practice guidelines and the barriers and facilitators to adherence: a mixed methods study protocol (2020) (4)
- Correlates of fever in patients (pts) receiving combined dabrafenib (GSK2118436) plus trametinib (GSK1120212) for V600 BRAF-mutant metastatic melanoma (MM). (2012) (4)
- Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. (1995) (4)
- A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy | NOVA. The University of Newcastle's Digital Repository (2010) (3)
- Reply to M. Perier-Muzet et al. (2014) (3)
- A Pooled analysis of 655 patients with advanced melanoma enrolled in keynote-001 : long-term efficacy of pembrolizumab (mk-3475) (2015) (3)
- Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (2018) (3)
- Australian doctors and nuclear war (1982) (3)
- Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma (2018) (3)
- Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM). (2017) (3)
- Targeting molecular mechanisms in cancer (2002) (3)
- The impact of multiple primary cutaneous melanomas on survival of 2,942 patients with metastatic melanoma. (2010) (3)
- Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix. (1992) (3)
- Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting (2019) (3)
- LESION-SPECIFIC PATTERNS OF RESPONSE AND PROGRESSION WITH ANTI-PD-1 TREATMENT IN METASTATIC MELANOMA (MM) (2014) (3)
- Hereditary melanoma and the search for the melanoma gene (1992) (3)
- Wild type and melanoma‐associated mutant p16INK4a proteins do not oligomerize in vivo (2009) (3)
- Pulmonary toxicity associated with bleomycin (1994) (2)
- Method of extracting DNA from fine needle aspirates of human solid tumors for Southern blot analysis. (1989) (2)
- Mitogen‐activated protein kinase dependency in BRAF/RAS wild‐type melanoma: A rationale for combination inhibitors (2020) (2)
- Genetic predisposition to melanoma (2003) (2)
- Repeated Suberythemal UVB Preexposure Protects against High-Dose UVB-Induced Expression of Vitamin D Receptor Protein in Human Skin (2011) (2)
- Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (2018) (2)
- Mutation and linkage analysis of CDKN2A and CDK4 in 119 Australian melanoma kindreds (1997) (2)
- Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM). (2017) (2)
- Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ” (2012) (2)
- IMMUNOBLASTIC LYMPHOMA IN HUSBAND AND WIFE (1980) (2)
- Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). (2019) (2)
- Epirubicin: A phase II study in recurrent small-cell lung cancer (2004) (2)
- Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets). (2019) (2)
- A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer (1988) (2)
- Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM). (2013) (2)
- bcGST—an interactive bias‐correction method to identify over‐represented gene‐sets in boutique arrays (2018) (2)
- Patterns of acquired resistance to anti-PD-1 antibodies in patients with metastatic melanoma (MM) (2015) (2)
- Prognostic value of quality of life (QL) scores in a clinical trial of dacarbazine (DTIC) with or without interferon‐alpha2a (IFN) in patients with metastatic malignant melanoma (MMM): 151 (1993) (1)
- The diagnostic applications of molecular biology (1989) (1)
- MC1Rgenotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study (2013) (1)
- Reply to E. Hindié and K.R. Hess. (2019) (1)
- Model for evaluation of tumour suppressor activity of CDNK2A alternate transcript (p16??) in melanoma: 324 (1997) (1)
- Mechanism of action of deoxyadenosine adenosine-deaminase inhibitor combinations - lympho-toxicity in G1 and G0 phases of cell-cycle (1982) (1)
- Carboplatin and VP16-213 with radiotherapy (RT) as initial treatment for patients with small-cell lung-cancer (SCLC) (1987) (1)
- Musculoskeletal immune‐related adverse events with the use of checkpoint inhibitors in malignancy (2020) (1)
- 23 Clinical Status of RAF/MEK Inhibitors (2012) (1)
- History of Melanoma (2018) (1)
- Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma. (2014) (1)
- Circulating tumor DNA (ctDNA) in patients (pts) with metastatic uveal melanoma (UM) treated with protein kinase C inhibitor (PKCi). (2020) (1)
- Sentinel node biopsy for melanoma: The medical oncology perspective. (2015) (1)
- BRAF/MEK inhibition in melanoma patients with rare BRAF mutations. (2018) (1)
- Drug treatment for melanoma: progress, but who pays? (2012) (1)
- Neoadjuvant systemic therapy for breast cancer: the Westmead experience (2018) (1)
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (1)
- Uveal melanoma cell lines depend on multiple signaling pathways for survival (2019) (1)
- Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients (2017) (1)
- IMPACT OF COMMON GENOMIC VARIANTS ON MELANOMA RISK PREDICTION (2014) (1)
- Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial. (2018) (1)
- BEST OF THE BEST RESEARCH 2016 ABSTRACTS. (2016) (1)
- CorrigendumAcquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition (2013) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Nobel Peace Prize to medicine (1985) (1)
- IMMUNOBLASTIC LYMPHOMA IN HUSBAND AND WIFE (1980) (1)
- Demonstration ofsomatic rearrangements andgenomic heterogeneity in humanovarian cancerbyDNA fingerprinting (1990) (0)
- Chromosome 10Q deletions in metastatic cutaneous melanoma are frequent and linked to 9p21 (CDKN2A) deletions: 464 (1997) (0)
- Contributors and Participants (1982) (0)
- Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance (2015) (0)
- Dialogue on nuclear disarmament (1982) (0)
- Transcriptional and Posttranscriptional Activation of Urokinase Plasminogen Activator Gene Expression in Metastatic Tumor Cells1 (2006) (0)
- Excerpts from the report of the chairman, Australian branch of MAPW annual general meeting, 16 Oct 1982. (1983) (0)
- Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo (2019) (0)
- Inhibition of Oncogenic BRAF Triggers Immunogenic Necrosis of Human Melanoma Cells (2013) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Effect of BRAF Mutation Status on Efficacy of nab-Paclitaxel versus Dacarbazine in Chemotherapy-Naive Patients with Metastatic Melanoma Treated in a Phase III Trsial (2013) (0)
- Germ cell tumours of the testis. (1992) (0)
- MELANOMA: NARROWING THE SIGHTS ON AN EVASIVE ENEMY (2006) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- P25 01 WP – REPLICA PLATING OF HUMAN MELANOMA CELLS COMBINED WITH IN SITU BROMODEOXYURIDINE (BUdR) LABELLING IN THE INVESTIGATION OF CELLULAR IONIZING RADIATION SENSITIVITY (1991) (0)
- Melanoma management in 2007. -letter- (2007) (0)
- Incorporation of 2'-deoxyadenosine into poly(a)RNA of human T-lymphoblasts (1982) (0)
- 2011 International Melanoma Congress (2011) (0)
- Circulating tumor DNA as a biomarker in metastatic melanoma patients treated with anti-PD1 antibodies (2016) (0)
- Heterogeneity of X-ray damage induction and repair in human malignant melanoma (MM) cell lines: 240 (1993) (0)
- Long-term survival and disease regression after adrenalectomy for adrenal metastases from melanoma. (2004) (0)
- Blood, biomarkers and beyond. Abstracts of the Medical Oncology Group of Australia Incorporated Annual Scientific Meeting. July 31-August 2, 2013. Melbourne, Victoria, Australia. (2013) (0)
- Concomitant CYP2D6 inhibitor use and plasma metabolite levels in breast cancer patients treated with tamoxifen (2012) (0)
- Genomic Landscape of Patient-matched Tumor and Circulating Cell-free DNA in Metastatic Melanoma (2019) (0)
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 (2014) (0)
- Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD) (2013) (0)
- Abstract 2650: In depth immune profiling of the response of melanoma to MAPK inhibition (2016) (0)
- Traitement par anticorps anti-PD-1 : pembrolizumab (MK-3475) chez 411 patients (pts) atteints de mélanome métastatique (2014) (0)
- Genotype-phenotype studies in CDKN2A (p16INK4a/p14ARF) mutation positive and negative Australian high risk melanoma families1 (2004) (0)
- IFNγ signaling sensitizes melanoma cells to BH3 Mimetics. (2023) (0)
- Differential expression of p16INK4A and p16b transcripts in hereditary melanoma families: 131 (1997) (0)
- Testicular ultrasound in patients with testicular germ cell tumours. (1994) (0)
- Clinical and Biological Efficacy of Recombinant Human Interleukin-21in Patients with Stage IVMalignant Melanoma without Prior Treatment: APhase IIaTrial (2009) (0)
- with combined dabrafenib and trametinib in a phase 1/2 clinical trial (2014) (0)
- Furine Deoxynucleoside Toxicity in Nondividing Human Lymphoid Cells (2006) (0)
- PO-368 Differential effects of immune activity on melanoma cell subtypes (2018) (0)
- Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma (2015) (0)
- Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation–positive melanoma with metastases to the brain (BRV116521). (2014) (0)
- Clinical and molecular genetics of melanoma: current status (1997) (0)
- Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes (1982) (0)
- Medical Heat for climate change (Viewpoint) (2006) (0)
- Progress in cancer control: the Alan Coates effect (2006) (0)
- Liquid biomarkers in melanoma: detection and discovery (2018) (0)
- Melanoma guide for GPs (2012) (0)
- Differences in the patterns of anti-pd1 (PD1) toxicity between tumor streams (2016) (0)
- Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing (2017) (0)
- The effect of UV-B on p53 and p21 in hereditary melanoma cell lines: 019 (1997) (0)
- The Ha-ras-1 oncogene and the molecular genetics of human melanoma. (1988) (0)
- Cutaneous melanoma/Authors' reply (2007) (0)
- Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia (2014) (0)
- A Randomised, controlled study to evaluate the effect of high-dose bosentan in patients with stage IV metastatic melanoma being treated with dacarbazine (2008) (0)
- Oncogene-induced senescence of primary human melanocyte (2010) (0)
- 3304 Metabolic activity in metastatic melanoma after long-term treatment with anti-PD-1 antibodies (2015) (0)
- Poly(A)+RNA as a possible target for deoxyadenosine induced G1/G0 lymphotoxicity. (1984) (0)
- Abstract 765: Multiple signalling pathways are active in BRAF/NRAS wild type melanomas (2018) (0)
- Early Detection of Cardiotoxicity in Cancer Patients Receiving Novel Chemotherapy and Immunomodulation by Measuring Global Longitudinal Strain (GLS) with Transthoracic Echocardiography (2018) (0)
- Correlates of outcome in patients with metastatic melanoma treated with dacarbazine (2008) (0)
- Issue information (2014) (0)
- Medical management of advanced melanoma (2005) (0)
- Molecular aspects of melanoma (2006) (0)
- Abstract A024: Protein microarrays for the immunological profiling of melanoma (2016) (0)
- From GWAS to genome sequencing: complementary approaches to identify melanoma predisposition genes (2012) (0)
- Abstract A154: Flow cytometric analysis of immune responses in the melanoma tissue biopsies before or during anti-PD1 immunotherapy (2019) (0)
- Non-coexpression of collagenase and transin in malignant epithelial cells. (1997) (0)
- BRAF Inhibitor Treatment BRAF-Mutant Melanoma Patients during Growth Factor Serum Levels in Dynamics of Chemokine , Cytokine , and (2014) (0)
- Mechanisms of oncogene-induced cellular senescence in primary human melanocytes (2010) (0)
- bcGST - an interactive bias-correction method to identify over-represented gene-sets in boutique arrays (2017) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). (2011) (0)
- CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen. (2012) (0)
- Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Metastatic Melanoma (MM) (2012) (0)
- Analysis of CDKN2A. CDKN2B, P16??, P21 and CDK4 in melanoma cells: 471 (1997) (0)
- 38. INTRALESIONAL MOLECULAR HETEROGENEITY IN A BRAF-MUTANT BRAF INHIBITOR RESISTANT MELANOMA: A CASE ILLUSTRATING THE CHALLENGES FOR PERSONALISED MEDICINE (2013) (0)
- families from three continents mutations: a GenoMEL study of melanoma-prone Features associated with germline CDKN2A (2007) (0)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (0)
- A novel model for metastasis suppression involving regulation of nuclear precursor messenger-RNA stability. (1995) (0)
- The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma (2014) (0)
- Molecular genetics of melanoma: 48 (1993) (0)
- Safety of combined exemestane and everolimus in postmenopausal hormone receptor positive metastatic breast cancer patients - a retrospective analysis (2014) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Abstracts of Melanoma 2010 Congress, the 7th International Melanoma Research Congress and the 4th Melanoma & Skin Cancer Centres Meeting. November 4-7, 2010. Sydney, Australia. (2010) (0)
- Health‐care interpreters and cancer (1989) (0)
- Guidelines for the Management of those at High Risk for Developing Cutaneous Melanoma (2007) (0)
- Toxicity-adjusted dose (TAD) administration of chemotherapy: Effect of baseline and nadir neutrophil count in patients with breast, ovarian, and lung cancer? (2011) (0)
- Long-term survival and disease regression after adrenalectomy for adrenal metastases from melanoma (2004) (0)
- Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma (2014) (0)
- Penetrance of CDKN2A mutations estimated using population-based Australian families (2009) (0)
- The impact of Granulocyte-Colony Stimulating Factor (G-CSF) and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on cancer therapy. In Accomplishements in Cancer Research 1989 Eds, General Motor Cancer Research Foundation, Philadelphia PAN, Lippincott, 1990, pp204-211. (1989) (0)
- Cutaneous toxicities of MAPK inhibitors: BRAF inhibitors, MEK inhibitors and combination therapy. A case series from an Australian institution (2013) (0)
This paper list is powered by the following services:
Other Resources About Richard F. Kefford
What Schools Are Affiliated With Richard F. Kefford?
Richard F. Kefford is affiliated with the following schools:
